Table 1 Clinicopathological characteristics of the entire cohort and first-line setting
Parameters | Total cohort, No. (%) | First line cohort, No. (%) |
|---|---|---|
All | 1133 | 675 |
Age at ICI started | ||
Median, y, range | 64.9 (28.4–98.7) | 64.8 (31.5–91.5) |
18–65 | 569 (50.2) | 342 (50.7) |
>65 | 564 (49.8) | 333 (49.3) |
Gender | ||
Male | 618 (54.5) | 374 (55.4) |
Female | 515 (45.5) | 301 (44.6) |
Tobacco use | ||
Never | 227 (20) | 132 (19.6) |
Former/current | 906 (80) | 543 (80.5) |
Histology | ||
LUAD | 862 (76.1) | 526 (77.9) |
LUSC | 213 (18.8) | 122 (18.1) |
Others | 58 (5.1) | 27 (4) |
Metastatic status at ICI start | ||
IVA | 486 (42.9) | 334 (49.5) |
IVB | 647 (57.1) | 341 (50.5) |
Liver metastasis at ICI start | ||
No | 972 (85.5) | 585 (86.7) |
Yes | 161 (14.2) | 90 (13.3) |
Brain metastasis at ICI start | ||
No | 824 (72.6) | 513 (76) |
Yes | 309 (27.3) | 162 (24) |
ICI treatment | ||
ICI-mono | 726 (64.1) | 300 (44.4) |
ICI-Chemo | 407 (35.9) | 375 (55.6) |
PD-L1 expression | ||
<1% | 254 (22.4) | 151 (22.4) |
1–49% | 277 (24.4) | 184 (27.3) |
≥50% | 240 (21.2) | 199 (29.5) |
Unknown | 362 (31.9) | 141 (20.9) |
